The patent for the diabetes drug Ozempic expires in India and China, allowing generic versions to enter the market. This move significantly lowers costs for millions of patients needing weight loss treatments like Wegovy. The expiration marks a major shift in the pharmaceutical landscape, potentially disrupting Novo Nordisk's revenue streams. India and China becoming generic hubs could pressure other major markets to follow suit, accelerating global access to affordable medications. Generic versions entering these large economies represent a substantial market opportunity for generic manufacturers and a challenge for branded drug companies.